Business Wire

ARTHUR-D.-LITTLE

6.3.2023 13:02:36 CET | Business Wire | Press release

Share
Arthur D. Little Delivers AV Market Insight in Latest Autonomous Mobility Journal

Arthur D. Little (ADL) has published the fourth edition of its Autonomous Mobility Journal, which looks at the latest developments in autonomous vehicles (AVs) and the market for autonomous mobility going forward.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005447/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Arthur D. Little: Autonomous Mobility Journal, Fourth Edition (Graphic: Business Wire)

As well as highlighting current industry dynamics, the journal also includes:

  • A special focus on robotaxis around the world
  • An overview of the AV market in Hong Kong
  • An interview with Prof. Omaimah Bamasag, Deputy of Transport Enablement at the Transport General Authority of the Kingdom of Saudi Arabia

While the AV market remains in its infancy and, like other industries, has suffered setbacks due to the Covid-19 pandemic and semiconductor shortages, companies are still working hard to advance AV technologies to the point of mainstream acceptance and deployment. The buoyancy of the global electric vehicle (EV) market also provides a technology pathway for autonomous mobility features to be more readily adopted in the coming years.

An interesting aspect of the autonomous mobility landscape is the high number of start-ups in this space that have gone public through special-purpose acquisition companies (SPACs) rather than more conventional IPOs. Many of these companies have shown fragility and lack of resilience in a difficult market context – however, it is hoped that increased focus on EV innovation by major OEMs will create additional traction in the AV market, and boost the prospects of AV start-ups.

ADL believes that the outlook for robotaxis is more positive, with “city robotaxis” which can operate in any mapped area of a city, even in extreme weather conditions, likely by 2027. “Anywhere robotaxis”, which can operate on unmapped or unmade roads, could also be a reality by 2030.

ADL’s analysis of the AV market in Hong Kong reveals how it has positioned itself as a leader in the autonomous mobility ecosystem through the successful coordination of key elements, including strategy, regulations, stakeholder integration, infrastructure and technology. Finally, Prof. OmaimahBamasag outlines Saudi Arabia’s ambitious goals for AV transport, including major autonomy-based initiatives such as the Neom and Red Sea projects in the Kingdom’s economic zone.

Joseph Salem, Partner in ADL’s Travel & Transportation practice, comments: “While the development of autonomous mobility solutions globally remains experiential, industry players are clearly on the lookout for technological and business model innovation to unlock value-creating use cases. In this journal, we provide a realistic overview of recent developments and industry dynamics, including the key considerations and challenges that the AV market currently faces. We hope it provides food for thought and look forward to feedback from our readers.”

The journal is available for download here: https://tinyurl.com/24cr7dxj

For further information, please visit www.adlittle.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005447/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OpZira, Inc. Welcomes Scott Thielman, PhD, as Vice President of Product Development30.6.2026 13:17:00 CEST | Press release

OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced that Scott Thielman, PhD, PE, has joined the company as Vice President of Product Development, effective May 1, 2026. Dr. Thielman brings a unique connection to OpZira’s origins. As Chief Technology Officer of Product Creation Studio, he directed the product development of LumiThera’s Valeda® Light Delivery System - the breakthrough photobiomodulation therapy for dry age-related macular degeneration whose acquisition by Alcon led to the creation of OpZira. His involvement with Valeda gives him firsthand knowledge of the science, clinical vision, and engineering decisions that shaped the technology platform from which OpZira was born. For more than 25 years, Dr. Thielman has directed the development of dozens of FDA-cleared medical devices across ophthalmology, neurostimulation, dermatology, urology, and surgical instrumentation, with partners including Olympus

L&T Technology Services Launches Ainfonix™ 4.0 to Unlock Engineering Intelligence Across Process Industries30.6.2026 12:45:00 CEST | Press release

The enterprise AI platform turns millions of engineering artifacts that run a plant into accurate, decision-ready data, delivering up to 85% extraction accuracy and full, audit-ready traceability L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced the launch of Ainfonix™ 4.0, a next-generation Engineering Intelligence platform for process industries. Unveiled at EI Live, LTTS’ flagship event that brings together analysts, industry leaders and engineering experts, Ainfonix™ 4.0 marks an important step in the company’s Enterprise AI and Engineering Intelligence strategy. As industrial enterprises accelerate AI adoption, decades of engineering knowledge remain trapped in fragmented drawings, specifications and technical records across disparate systems. Without trusted and accessible engineering data, organizations struggle to realize the full value of AI, automation and digital transformation

Klick Health Acquires Oxford PharmaGenesis, Bringing Together Unsurpassed Scientific-to-Commercial Capabilities for Life Sciences Clients30.6.2026 12:03:00 CEST | Press release

Bonded by breakthroughs and a laser focus on their people and clients, leading independent agencies join forces to deliver accelerated commercial success through broadened medical affairs and communications, market access, and RWE/HEOR offerings; the most advanced degree holders; expanded global reach; and the best workplace culture around Focused on taking life sciences companies into the future, Klick Health today announced its acquisition of Oxford PharmaGenesis, the market-leading HealthScience communications consultancy renowned for its scientific and medical expertise, as well as value and market access consulting throughout Europe, Asia-Pacific, and North America. Today’s news brings together two of the leading independent agencies in life sciences. With Oxford PharmaGenesis’ expertise across medical affairs and market access, and Klick's strength in commercial strategy, medical, creative, digital, analytics, and experience design, they can deliver an unparalleled scientific-to-

BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma30.6.2026 12:00:00 CEST | Press release

Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), meeting the primary endpoint of PFSMANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusionsFull results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA® (zanubrutinib) plus rituximab versus bendamustine plus rituximab (BR) in adult patients with previously untreated mantle cell lymphoma (MCL). MANGROVE is the first Phase 3, global, randomized trial to evaluate a BTK inhibitor-based chemotherapy-

Hytera Debuts SC700 Smart 4G Body Camera at CCW 202630.6.2026 11:30:00 CEST | Press release

Hytera, a leading global provider of critical communications technologies and solutions, officially debuted its SC700 Smart 4G Body Camera at Critical Communications World (CCW) 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630283236/en/ Hytera's latest SC700 Smart 4G Body Camera Public safety operations are increasingly moving toward real-time, connected workflows, where communication, video, and situational awareness are integrated to support a faster and more coordinated response in the field. The SC700 is designed to support this shift. It enables live video, location sharing and push-to-talk communication, helping connect frontline officers with control rooms. Integrated with Hytera HyTalk PoC System, it also supports communication across broadband and PMR users to improve coordination across teams. It also features Intelligent Scene Aware, which can detect abnormal situations such as man down, inactivity, or

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye